Community for private sperm donation, co-parenting and home insemination – respectful, direct and discreet.

Author photo
Philipp Marx

Immunology in pregnancy: what is actually proven

On the internet it often sounds as if the immune system will simply reject a pregnancy and needs to be switched off. Medically, it is more nuanced: pregnancy succeeds with a carefully regulated immune response. This article explains what is supported by evidence, where diagnostics have limits, and why many immune treatments in fertility care are approached with caution.

A doctor explains the role of the immune system in early pregnancy using a simple sketch

What do immunological problems in pregnancy mean?

In medicine, the phrase rarely means a general rejection. It usually refers to specific mechanisms that can influence implantation, placental development, or the stability of a pregnancy.

It is important to distinguish between immunological factors that are well defined, reliably diagnosable and treatable, and markers or theories that may appear plausible but have not been shown in studies to reliably improve live birth rates.

Immune system in pregnancy: not switched off, but adjusted

Pregnancy is not a state of immune suppression. The body adjusts immune responses in a targeted way so that protection against infections is maintained while a stable placenta can form.

Part of the regulation happens locally in the uterine lining. There, certain immune cells support vascular adaptation and early placental processes. Balance, location and timing are therefore crucial.

Why the placenta is immunologically so special

The placenta is not a passive filter, but an active boundary tissue between mother and pregnancy. Cells from the embryo, maternal blood vessels and immune cells all have to work together without the body switching off defence against infection completely.

That is why pregnancy is not about more or less immunity, but about the right immune state in the right place. Local immune cells help with remodelling, tolerance and supply, while systemic defence remains intact. PubMed: Immunoediting in pregnancy

When immunology becomes truly relevant in fertility medicine

Immunological questions become particularly important when miscarriages recur or when there are patterns suggesting specific complications. In those cases a structured evaluation is worthwhile, rather than interpreting isolated values in isolation.

A solid reference framework for managing recurrent pregnancy loss is the ESHRE guideline. It also helps avoid overdiagnosis and focus tests on those that can actually change decisions. If you want the broader picture around repeated loss, the article on miscarriage is also useful. ESHRE: Guideline on recurrent pregnancy loss.

The best-supported immunological factor: antiphospholipid syndrome

If there is one area where immunology in pregnancy is clearly clinically relevant and treatable, it is antiphospholipid syndrome. This is an autoimmune condition in which certain antibodies are associated with increased risks of blood clots and pregnancy complications.

Accurate diagnosis is important. APS is not diagnosed on the basis of a single lab result. Usual practice uses clinical criteria and repeatedly positive laboratory tests at defined intervals.

What doctors look for in APS

  • recurrent miscarriages or later pregnancy losses
  • blood clots or other clotting events
  • pregnancy complications such as pre-eclampsia or growth restriction
  • a clear antiphospholipid antibody profile with lupus anticoagulant, anticardiolipin, or anti-beta-2 glycoprotein I antibodies

The real challenge is not finding a positive result, but deciding whether the pattern truly fits APS. That is where careful medicine differs from jumping to conclusions on the basis of a few numbers.

When APS is confirmed, treatment during pregnancy is planned individually. Low-dose aspirin and heparin are commonly used, depending on the risk pattern and clinical history. NHS: APS treatmentACOG: Antiphospholipid syndrome.

This is a good example of evidence-based medicine: a clear indication, standardised diagnostics and therapy with a reasoned benefit-risk assessment. A recent review describes APS as one of the most clearly proven immunological risk areas in pregnancy. PubMed: APS in pregnancy review

Autoimmunity and fertility: common, but not automatically the cause

Autoimmune diseases and autoantibodies are common, and many affected people have children without problems. At the same time active disease, inflammation or particular constellations can increase risks.

The professional perspective therefore asks not only whether an antibody is detectable, but whether that finding is clinically relevant in your situation and whether treatment actually improves the prognosis.

What matters with known autoimmune disease

  • Is the disease currently stable or active?
  • Which medicines are needed even before pregnancy?
  • Is there a history of blood clots or organ involvement?
  • Who is involved in the pregnancy care, for example gynaecology, haematology or rheumatology?

Safe pregnancy planning therefore does not begin with panic about the immune system, but with an honest look at disease activity, accompanying conditions and the right specialist input.

Why NK cells, immune profiles and immunotherapies are so controversial

A large part of the discussion concerns tests and therapies offered in some clinics despite inconsistent evidence. These include blood tests for natural killer cells, cytokine profiles or treatments such as intralipid infusions and intravenous immunoglobulins.

The core problem is translating laboratory values into clinical decisions. An abnormal value does not automatically prove causation. And an immune therapy is not automatically effective just because it looks plausible in theory.

Independent assessments are valuable here. The HFEA evaluates immunological tests and treatments as add-ons with caution because benefits and safety vary by intervention and population and are not convincingly established. HFEA: Immunological tests and treatments for fertility.

Which diagnostics are often sensible and which add-ons are not

A good evaluation starts with the question of whether a finding would actually change a decision. That is why the first step in practice is history, previous pregnancies, blood clots, known autoimmune disease and relevant medicines.

Often sensible

  • targeted antiphospholipid testing when the history fits
  • basic evaluation after repeated pregnancy losses
  • targeted search for other clear causes such as genetic, anatomical or hormonal factors
  • specialist input when autoimmune disease is already known

Often not sensible as routine

  • broad NK-cell panels without a clear question
  • vague cytokine panels as a fishing exercise
  • Intralipid infusions or IVIG without solid indication
  • always adding new immune markers simply because the first value was normal

The ESHRE recommendations on add-ons in reproductive medicine show exactly this pattern: where evidence is lacking, tests and treatments should not become routine. PubMed: ESHRE good practice recommendations on add-ons

What matters is the distinction between real diseases such as APS and vague add-ons. APS belongs in medical diagnostics and treatment, not in the box with lifestyle extras.

Realistic expectations: what assessment can and cannot do

After miscarriages many people hope for a clear explanation. Often the cause is multifactorial, and a clear, treatable diagnosis is not always found.

  • A good assessment can identify treatable causes, for example APS.
  • It can help avoid unnecessary or risky measures.
  • It can structure decisions and make expectations more realistic.

Even if causes remain unclear, the result is not without value. It may mean that certain costly or burdensome therapies without solid indication are avoided because they are more likely to harm than help.

What to note before an appointment

For immunological questions, a clean timeline helps more than a loose collection of laboratory values. The most important details are often simple, but they matter greatly for interpretation.

  • How many pregnancies were there, and in which week did they end?
  • Were there blood clots, pre-eclampsia, growth restriction or preterm births?
  • Which antibodies, medicines or diagnoses are already known?
  • Which infections, procedures or new symptoms happened before the loss?

The clearer this framework is, the easier it becomes to decide whether immunology is actually the main issue or only one part of a larger picture.

Myths and facts: immunology in fertility care

  • Myth: The immune system must be broadly suppressed when trying to conceive. Fact: Pregnancy requires a regulated immune system. Blanket immunosuppression without diagnosis can increase risk.
  • Myth: If the body rejects the pregnancy, it is certainly immunological. Fact: Miscarriages have many causes, often genetic or developmental. Immunology is only one part of the spectrum.
  • Myth: An abnormal NK-cell value proves an implantation disorder. Fact: The clinical usefulness of many NK measurements is unclear. Methods, thresholds and their predictive value for live births are not consistent.
  • Myth: Uterine NK cells are the same as NK cells in blood. Fact: Local immune processes in the uterus are not automatically reflected by blood values.
  • Myth: The more immune markers are tested, the better. Fact: More tests often only increase random abnormalities. What matters is whether a finding leads to a clear, evidence-based consequence.
  • Myth: Detecting an antibody means immunotherapy is necessary. Fact: Diagnostic criteria and clinical context are decisive. Especially for APS, defined criteria and repeated confirmation are needed.
  • Myth: Intralipid is harmless and helps with immune problems almost always. Fact: Robust evidence is lacking for many situations, so independent bodies assess effectiveness cautiously. HFEA: Assessment of immunological add-ons.
  • Myth: IVIG is the standard solution for recurrent miscarriage. Fact: Evidence reviews find no clear benefit for live birth rates in many groups, and risks and costs are relevant. Cochrane: Immunotherapy for recurrent miscarriage.
  • Myth: If immunology plays a role, the prognosis is necessarily poor. Fact: Prognosis depends strongly on age, the cause profile and accompanying factors. Treatable causes can substantially change risk.
  • Myth: A short course of steroids is a low-risk trial. Fact: Corticosteroids are effective drugs with side effects. Caution is sensible without a clear indication.

What a professional diagnostic pathway typically looks like

Good care does not start with specialist panels but with history, basic diagnostics and findings that actually change treatment. For recurrent pregnancy loss many centres follow guidelines that weigh diagnostics and treatment by evidence. ESHRE: RPL Guideline.

Principles to remember

  • First clarify which question needs answering and which decision depends on it.
  • Prefer tests that are standardised and have clear criteria.
  • When considering therapies always discuss benefits, risks and alternatives, not just theory.
  • For add-ons ask for evidence relevant to your specific situation, not only general success figures.
  • With suspected APS ensure correct diagnostics and avoid quick interpretations.

A good second opinion is one that does not offer a ready-made explanation immediately. It first asks about the loss pattern, clotting events, previous conditions and what can actually be inferred from the result.

Safety: Why more immunotherapy is not automatically better

Immune-modulating therapies are not neutral. They can have side effects, interact with other conditions, or be appropriate in pregnancy only for clear indications.

Serious medicine is therefore cautious. Not out of passivity, but because the decisive standard is whether, in the end, more healthy births occur without increasing avoidable risks. Costly-sounding add-ons without a clear indication are not progress; they are often only more uncertainty.

When you should seek medical advice promptly

A timely assessment is sensible for recurrent miscarriages, a history of blood clots, severe pregnancy complications or known autoimmune disease, especially if the disease is active.

Even if immune therapies are offered as a quick fix, a second structured assessment is worthwhile. Good medicine explains the indication, states uncertainties and discusses risks openly. The same applies when you have plenty of laboratory data but still no clear plan.

Conclusion

The body does not work against pregnancy by default. But certain immunological mechanisms can play a role, and some are well treatable, foremost antiphospholipid syndrome. If you are evaluating repeated miscarriages or autoimmune disease, what you need is not loud immune theory, but clean diagnostics and treatment with a clear indication.

Disclaimer: Content on RattleStork is provided for general informational and educational purposes only. It does not constitute medical, legal, or other professional advice; no specific outcome is guaranteed. Use of this information is at your own risk. See our full Disclaimer .

Common questions about immunology in pregnancy

Immunological factors can be involved in individual cases, but most implantation problems cannot be traced back to a single immune value, which is why structured evaluation is more important than a blanket suspicion.

Antiphospholipid syndrome is a central, well-supported immunological factor that can be associated with pregnancy complications and is treated specifically when the diagnosis is confirmed.

The clinical benefit is unclear in many situations because measurement methods, thresholds and the link to pregnancy outcomes are not consistent, so such tests should be interpreted critically.

Robust evidence is lacking for many scenarios, and the decision should therefore be based on individual indication and a sober benefit-risk assessment.

IVIG is not a general standard solution because benefit and safety vary by situation and the therapy can have relevant risks and costs.

Many guidelines consider two or more pregnancy losses as a reason for structured evaluation, although definitions and approaches vary by system and history.

Targeted immune therapies are only sensible when there is a clear indication, because blanket immunosuppression without diagnosis is more likely to increase risks than improve chances.

No. The context always matters: the laboratory value, symptoms, pregnancy history and other findings together determine whether the result is clinically meaningful. A single positive value does not explain a pregnancy complication on its own.

Not as a broad screening strategy. Targeted testing makes sense when the history points to it, for example after recurrent losses, thrombosis or known autoimmune disease. Broad fishing expeditions usually add noise rather than clarity.

Especially when APS is suspected, when there is a history of thrombosis, when autoimmune disease is active, or when pregnancy has already been complicated by pre-eclampsia, growth restriction or other significant findings.

Yes, often it can. The key factors are disease activity, medication and specialist follow-up. Many people with autoimmune disease have successful pregnancies when the situation is planned well.

Recurrent miscarriages, a history of blood clots, severe pregnancy complications or known autoimmune disease are reasons to plan a timely structured evaluation.

Because immunology is complex and many hypotheses sound plausible, but not every measurable deviation is a cause or reliably leads to more live births when treated.

Ask for evidence relevant to your specific situation, ask about risks and alternatives, and choose to be informed rather than acting quickly on single lab values or general success claims.

Download the free RattleStork sperm donation app and find matching profiles in minutes.